Center Report to the SNMMI Board of Directors  
January 2021  
Therapy Center of Excellence

**Center Mission**: Therapy CoE is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. Specifically, the center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:  
(a) Provides a forum for members with similar interests  
(b) Provides expertise in TRT  
(c) Fosters research and education in TRT  
(d) Provides outreach to other professionals and organizations  
(e) Nurtures new membership in SNMMI

**Center Mission and SNMMI’s Strategic Plan**: The work of the Therapy Center applies to the following goals and objectives in SNMMI’s Strategic Plan:

**Goal A**: SNMMI members are known for high-quality, value-driven performance and delivery of patient-centered nuclear medicine practice.  
Objective 4. Expand continuing education options for practitioners.

**Goal B**: SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.  
Objective 1: Encourage and promote research in the field  
Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.

**Goal E**: Patients and the medical community recognize the value of nuclear medicine, molecular imaging and radionuclide therapy.  
Objective 3. Improve collaboration with other medical societies.
Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

Objective 1: Strengthen membership numbers.
   d. Ensure enthusiasm.
      iii. Create a sense of community and networking opportunities among our members.

Therapy CoE President: Dan Lee, MD

SNMMI Board members appointed to Therapy CoE Board: Richard Wahl, MD, FACNM; Satoshi Minoshima, MD, PhD; Giuseppe Esposito, MD, MBA

Date of Last meeting: December 2020

Date of Next meeting: January 23, 2021

Update on Programs of the Center:

2020 SNMMI Mid-Winter Meeting CE sessions
   • Response Assessment in the Setting of PRRT

2020 SNMMI Annual Meeting CE Sessions
   • Prostate Theranostics
   • Therapy YIA Sessions

2021 SNMMI MWM Meeting CE Session – Therapy Focus
   • Nuts & Bolts of IV Radiopharmaceutical Therapy Administration
   • Prostate Cancer PSMA Therapy
   • Update on Radionuclide Therapies in Pediatrics: Current Status and Novel Applications
   • Updates and Clinical Applications of PRRT for NET
   • Radioiodine Therapy for Differentiated Thyroid Cancer (CORT)

Outreach Meetings:
   • Multilateral Conference of Differentiated Thyroid Cancer

Therapy Strategic Planning Task Force
Through various components within the SNMMI, including, but not limited to the SNMMI Therapy Center of Excellence, Research and Discovery Domain, Workforce Pipeline and Lifelong Learning Domain, Advocacy Domain and Quality of Practice Domain, the SNMMI will serve as THE leader in the implementation of radiopharmaceutical therapy (RPT) as an important part of personalized patient care. SNMMI will provide professional networking, educational opportunities and standards for practice in the area, while simultaneously serving as a resource for development and implementation of Society policy. The organization also has a role to play in fostering partnerships with organizations such as the AAPM, ASTRO, RSNA, ASCO, ACR, WARMTH, and collaborating with agencies such as the NCI, FDA, NRC and DOE.
Performing radiopharmaceutical therapies is becoming more complex and requires more facilities, resources, experience and training than imaging alone. Maintaining and growing the SNMMI’s role as the thought, scientific and practice leader in this area should continue to be strongly supported by the SNMMI.

Nuclear medicine physicians will assume a higher profile in the public and within healthcare systems, so that more people understand what we offer. Specifically, for RPT of patients with cancer, we need recognition as specialists to whom oncology patients are referred for evaluation and/or RPT treatment.

**Action Items in Progress/Pending:**

- Establishing the Therapy Center newsletter
- Follow-up with NCI on the TRT meeting
- ThyCa Initiative: bringing together local nuclear medicine physicians and ThyCa chapter facilitators to coordinate pro bono presentations by nuclear medicine physician in the region of the various ThyCa chapters on radioiodine imaging and therapy. Develop educational modules for these speakers.
- Continue the work of the Therapy Strategic Planning Task Force to align SNMMI as the leader in radiopharmaceutical therapy

**Action Items Completed:** See programs above

**Recommendations/Questions for the Board of Directors:** N/A

**Other Comments:** N/A